ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,344.29
-0.62%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE
  6. Hikma Pharmaceuticals Plc (HIK)

  7. Hikma Pharmaceuticals Plc (HIK) Noticias

HIK

Hikma Pharmaceuticals (HIK)

Hikma Pharmaceuticals Plc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:HIK
FechaHoraFuenteTítuloSímboloCompañía
25/04/202408:28RNS Regulatory NewsHikma Pharmaceuticals Plc Result of AGMLSE:HIKHikma Pharmaceuticals Plc
25/04/202404:15Alliance NewsAlliance NewsHikma Pharmaceuticals backs outlook after making strong start to 2024LSE:HIKHikma Pharmaceuticals Plc
25/04/202401:00RNS Regulatory NewsHikma Pharmaceuticals Plc Trading StatementLSE:HIKHikma Pharmaceuticals Plc
17/04/202404:42RNS Regulatory NewsHikma Pharmaceuticals Plc Director/PDMR ShareholdingLSE:HIKHikma Pharmaceuticals Plc
15/04/202410:43RNS Regulatory NewsHikma Pharmaceuticals Plc Hikma appoints new President of Generics businessLSE:HIKHikma Pharmaceuticals Plc
02/04/202403:50RNS Regulatory NewsHikma Pharmaceuticals Plc Block listing Interim ReviewLSE:HIKHikma Pharmaceuticals Plc
22/03/202404:21RNS Regulatory NewsHikma Pharmaceuticals Plc Annual Financial Report and Notice of AGMLSE:HIKHikma Pharmaceuticals Plc
01/03/202404:17RNS Regulatory NewsHikma Pharmaceuticals Plc Total Voting RightsLSE:HIKHikma Pharmaceuticals Plc
22/02/202403:42Alliance NewsAlliance NewsTOP NEWS: Hikma boosts dividend after year of "significant progress"LSE:HIKHikma Pharmaceuticals Plc
22/02/202401:09Alliance NewsAlliance News*Hikma Pharmaceuticals says core operating profit to be in range of USD660m to USD700mLSE:HIKHikma Pharmaceuticals Plc
22/02/202401:08Alliance NewsAlliance News*Hikma Pharmaceuticals expect revenue to grow in the range of 4% to 6%LSE:HIKHikma Pharmaceuticals Plc
22/02/202401:08Alliance NewsAlliance News*Hikma Pharmaceuticals confident that strategy will continue to deliver growth in 2024LSE:HIKHikma Pharmaceuticals Plc
22/02/202401:07Alliance NewsAlliance News*Hikma Pharmaceuticals declares FY dividend of 73 US cents per share vs 56 cents YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202401:06Alliance NewsAlliance News*Hikma Pharmaceuticals 2023 pretax profit USD520m vs USD233m YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202401:06Alliance NewsAlliance News*REPEAT: Hikma Pharmaceuticals 2023 revenue USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202401:05Alliance NewsAlliance News*Hikma Pharmaceuticals 2023 USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202401:00RNS Regulatory NewsHikma Pharmaceuticals Plc Final ResultsLSE:HIKHikma Pharmaceuticals Plc
21/02/202412:20UK RegulatoryHikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facilityLSE:HIKHikma Pharmaceuticals Plc
20/02/202411:24Alliance NewsAlliance NewsEARNINGS PREVIEW: Eyes on Hikma's outlook ahead of full-year resultsLSE:HIKHikma Pharmaceuticals Plc
05/02/202406:00UK RegulatoryHikma announces US launch of COMBOGESIC® IVLSE:HIKHikma Pharmaceuticals Plc
05/02/202402:46RNS Regulatory NewsHikma Pharmaceuticals Plc Notice of ResultsLSE:HIKHikma Pharmaceuticals Plc
01/02/202414:00Alliance NewsAlliance NewsEARNINGS AND TRADING: Tandem FY sales down 17%; Hikma's opioid dealLSE:HIKHikma Pharmaceuticals Plc
01/02/202412:22RNS Regulatory NewsHikma Pharmaceuticals Plc Agreement in Principle for US Opioid SettlementLSE:HIKHikma Pharmaceuticals Plc
29/12/202301:00UK RegulatoryHikma Pharmaceuticals Plc Company Secretary ChangeLSE:HIKHikma Pharmaceuticals Plc
02/11/202303:53Alliance NewsAlliance NewsTOP NEWS: Hikma Pharmaceuticals upgrades Generics and Branded guidanceLSE:HIKHikma Pharmaceuticals Plc
03/10/202306:00PR Newswire (US)Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the USLSE:HIKHikma Pharmaceuticals Plc
30/08/202311:55Alliance NewsAlliance NewsTOP NEWS: M&S returns to FTSE 100 after four years, Persimmon exitsLSE:HIKHikma Pharmaceuticals Plc
23/08/202308:07Alliance NewsAlliance NewsIN DEPTH: M&S set for blue-chip return as Hikma-Dechra yo-yo continuesLSE:HIKHikma Pharmaceuticals Plc
22/08/202311:26Alliance NewsAlliance NewsTOP NEWS: M&S set to be FTSE 100 outfit again but Persimmon may fallLSE:HIKHikma Pharmaceuticals Plc
10/08/202307:28PR Newswire (US)Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North AfricaLSE:HIKHikma Pharmaceuticals Plc
 Showing the most relevant articles for your search:LSE:HIK

Su Consulta Reciente

CCOM
OILBRENT
Brent Oil
NYSE
DIS
Walt Disney
COIN
SOLUSD
Solana
NYSE
AXP
American Express
NYSE
KO
Coca Cola
NYSE
JPM
JP Morgan Chase
COIN
ETHUSD
Ethereum
AMEX
SPY
SPDR S&P 500
USOTC
BNPQY
BNP Paribas (QX)
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
MRK
Merck
NASDAQ
MSFT
Microsoft
NYSE
XOM
Exxon Mobil
AMEX
XLF
Financial Select Sector
SPI
SP500
S&P 500
NASDAQ
GOOGL
Alphabet
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados